Taiwan
Expertise in antisense oligonucleotide (ASO) therapeutics, LNP delivery systems, and translational cancer immunotherapy with focus on preclinical strategy development. Experienced in cell-based assays, flow cytometry, molecular biology, and in vitro/in vivo models for therapeutic evaluation and mechanism validation. Strong background in tumor xenograft and transgenic mouse models, mechanistic biology, and cross-functional R&D collaboration, supported by publications and patents.
Led cross-functional PD/QA/QC teams to drive project progression, data integrity, and regulatory compliance. Investigated Acemannan’s immunomodulatory and therapeutic potential, supporting translational development, formulation optimization, and indication expansion.
Developed ex vivo and in vivo LNP-based gene therapy approaches targeting hematopoietic stem cells (HSCs) for AML treatment. Led animal study design and execution, including IACUC protocols, compliance, and program coordination.
Introduced advanced laboratory instruments and reagents, including NGS systems, LNP platforms, fluorescence imaging tools, and molecular biology reagents. Provided technical support and product training for academic and biotech clients.
Optimized STAT3-targeting ASO therapeutics and evaluated combination strategies for glioma immunotherapy to support translational development. Profiled glioma-associated myeloid and T cells in inducible STAT3 knockout mouse models to identify immune mechanisms and therapeutic biomarkers
Utilized Kras, EGFR, p53, and Pten mutated transgenic mouse models to study lung tumorigenesis. Performed gene profiling of Specificity protein-1 (Sp1)-knockout astrocytes and assessed effects on neuronal development.